Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWE Adjuvant in Seasonal Influenza Vaccine
NCT05035680Phase 1Withdrawn
- Sponsor
- Gates Medical Research Institute
- Start
- Jul 2022
- Primary completion
- Mar 2023
01
Overview
Phase 1, randomised, double-blind trial of SWE + QIV in influenza (3 arms), sponsored by Gates Medical Research Institute. Primary endpoints: Severe/serious adverse event (SAE) burden at 7 days and Hemagglutinin inhibition (HI) antibody response at Day 29. Planned start Jul 2022; status: withdrawn.
02
Drugs
SWE + QIV
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05035680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035680.